obesity drug news today glp-1 october 2025 therapies are changing care. What does WHO recommend? Here's what you need to know What is the pipeline for
Description
These are sometimes marketed as cheaper or more accessible alternatives, but quality and safety can vary
When theres more stuff in your blood in this case sugar and you suddenly reduce the amount of stuff in the blood, it causes rapid shifts in fluid between blood vessels and cells in the eye, he said
If elevated risk is present, discontinuation should be considered, weighing risks of metabolic decompensation
As prices become more affordable, these drugs could transform chronic disease management for millions
The GLP-1 class cardiovascular track record Context from the broader GLP-1 receptor agonist class is relevant
Hayes MR, Borner T, De Jonghe BC
